Tobias Banaschewski, MD, PhD, is Professor of Child and Adolescent Psychiatry at the Medical Faculty Mannheim of the University of Heidelberg and Medical Director of the Department of Child and Adolescent Psychiatry as well as Deputy Director of the Central Institute of Mental Health in Mannheim, Germany. Dr. Banaschewski studied psychology and medicine at the University of Marburg in Germany. He worked as Clinical Assistant in Adult Psychiatry in Marburg and as Clinical and Research Assistant in Child and Adolescent Psychiatry at the University of Göttingen, Germany.
Prof. Banaschewski is Chair of the European Network for Hyperkinetic Disorders (EUNETHYDIS), Member of the European College of Neuropsychopharmacology, Board committee member of the German ADHD network and a Past-President of the German Society of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy (DGKJP). His main research foci are on the psychopathology, neurobiology, neuropsychology, neurophysiology and psychopharmacology treatment of ADHD, autism and comorbid disorders. He co-authored more than 550 peer-reviewed papers and received the Kramer-Pollnow-Award in 2003, the August-Homburger Award in 2014 and the Saarland ADHD-Research Award in 2016.

Dr Marta Di Forti is a Senior Lecturer at the Dept of Social, Developmental and Genetic Research, Institute of Psychiatry, and Honorary Consultant Adult Psychiatrist, Lambeth Community team, South London and Maudsley NHS foundation Trust. She leads the first and only Cannabis Clinic for patients with Psychotic disorders in UK. She was recently awarded a MRC Senior Research Fellowship to expand her research in the role of cannabis use in psychosis and its underlying biology. With her team she showed for the first time that use of high potency types of cannabis e.g. "skunk" carries a higher risk of psychosis than use of traditional types and that it affects rates of Psychotic disorders across Europe. Though it still remains unclear who are those cannabis use most at risk. Her future work aims to investigate the interaction between cannabis use and genes predisposing to schizophrenia, and how cannabis changes the epigenome.

Sinan Guloksuz, MD, PhD is an Associate Professor of Psychiatry at the Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, and the Department of Psychiatry, Specialized Treatment Early in Psychosis (STEP) Program, Yale University School of Medicine. With a background in clinical psychiatry and epidemiology, Dr. Guloksuz’s main research focus has been on understanding the mechanisms underlying mental health outcomes and investigating the contribution of exposome and genome to multidimensional phenotypes in the general population cohorts (EFPTS, EDSP, TWINSCAN, NEMESIS-I/II, UK Biobank, ABCD) and large case-control samples (GROUP, EUGEI, Athens FEP cohort). His work in the EUGEI using the polygenic risk score for schizophrenia has provided the initial molecular evidence for gene-environment interaction in schizophrenia. His recent series of work adopting the exposome framework in psychiatry for the first time resulted in a cumulative environmental liability score (exposome score for schizophrenia) that has been tested for predictive performance and stratification properties in the general population, as well as clinical utility in first episode psychosis. The second body of his work has been in the areas of clinical trials and service research for psychosis spectrum disorder. His work has resulted in over 140 peer-reviewed publications, 12 book chapters, and awarded with international prizes from WPA, EPA, and APA. He is the WorkPackage Leader (Gene-Environment Interaction) in the recently ZonMw-funded FEP project: OPHELIA, and a consortium member in the EU Horizon 2020 Pharmacogenetics in Psychiatry project. He has ongoing active roles in professional organizations, such as the Schizophrenia International Research Society and currently serves as the Associate Editor of the npj Mental Health Research and the Editorial Board Member of the British Journal of Psychiatry and the PLOS One.

John M. Kane, MD. is the Senior Vice President for Behavioral Health Services at Northwell Health in New Hyde Park, New York. He is Chairman of the Department of Psychiatry at The Zucker Hillside Hospital in Glen Oaks, New York. Additionally, he is Professor and Chairman of Psychiatry at The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell.
Dr. Kane earned his medical degree from New York University in New York, New York, and completed his internship and residency in Psychiatry at The Zucker Hillside Hospital. He is a Diplomate of the American Board of Psychiatry and Neurology.
Dr. Kane is the recipient of many awards, including the Lieber Prize, The APA’s Kempf Award and Foundations Prize, the New York State Office of Mental Health Lifetime Achievement Award, The Dean Award from the American College of Psychiatrists. He has served as President of the American Society of Clinical Psychopharmacology, the Psychiatry Research Society and the Schizophrenia International Research Society.
Dr. Kane has been the principal investigator for research projects focusing on schizophrenia, psychobiology and treatment, recovery, and improving the quality and cost of care. He is the author of over 700 peer-reviewed papers and serves on the editorial boards of numerous journals.

Robin Murray is a Professor at the Institute of Psychiatry, London. He was one of the first to suggest that schizophrenia was in part a neurodevelopmental disorder, and has contributed to the understanding that obstetric events, drug abuse and social adversity dysregulate striatal dopamine and thus increase the risk of psychosis. He has written over 800 articles, not all of them boring! He has supervised 81 PhDs, and 44 of his students have become full professors. He is one of only 5 psychiatrists ever to be elected a Fellow of the Royal Society and received a knighthood in 2011.

Paolo Fusar-Poli is a Professor of Preventive Psychiatry at the Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King's College London (KCL), where he heads the Early Psychosis: Intervention and Clinical-detection Laboratory (EPIC Lab). He is also a consultant psychiatrist in the Outreach And Support In South-London (OASIS) mental health service at the South London and Maudsley NHS Foundation Trust, one of the oldest and largest preventive services worldwide. Much of his research utilises evidence-based medicine, clinical prediction, neuroscience and experimental therapeutics and aims to develop new and effective strategies to improve the prevention of mental disorders.
He completed his medical studies, psychiatric training, PhD and first consultant job at the University of Pavia, Italy, where he is Associate Professor. During his PhD he moved to the IoPPN: this collaborative relationship has continued ever since.
He is author of about 400 publications in PubMed journals, with h-index of 94 (up to 2021), invited speaker and/or chairman in several national and international scientific conferences and principal investigator or co-investigator of national and international grants focused on the prevention of mental disorders. He chairs national and international clinical research networks for the prevention of mental disorders.
• 2015, 2016, 2017, 2018, 2019, 2020 – Highly Cited Researcher (top 1% by citations for field and year in the Web of Science)
• 2019 ranked as the number two expert in psychosis in the world (top 0.004% out of 49,886 ranked scientists up to 2021)
• 2012 and 2019 External Advisory, DSM-5 and DSM-5TR Psychosis Working Group, US.

Dr Nikos Scarmeas was born and raised in Athens Greece. After obtaining an M.D. degree from the University of Athens he moved to the US and had Neurology residency training and then a 2-year clinical fellowship in Aging and Dementia at Columbia University Medical Center. He also completed a Masters degree in Biostatistics – Epidemiology at the Mailman School of Public Health at Columbia University.
Dr Scarmeas joined the faculty of Columbia University in 2002. He currently shares his research time between National and Kapodistrian University of Athens and Columbia University. His educational and clinical work includes seeing elderly patients with dementias and cognitive dysfunction, supervising and teaching of Medical students and Neurology residents at National and Kapodistrian University of Athens.
His research interests include cognitive reserve (i.e. how higher IQ, education, more demanding occupational attainments, or more engagement in cognitive-social-physical leisure - lifestyle activities can help elderly cope better with the damage caused to their brains by Alzheimer’s disease and aging and therefore reduce their risk for dementia and slow down their rates of cognitive and functional decline). In addition, he has extensively investigated the contribution of diet (in particular composite dietary patterns such as a Mediterranean-type diet and others) and physical activity in dementias and healthy aging.
Dr Scarmeas has been the Principal Investigator in studies funded by either the Alzheimer's Association (IIRG) or the NIH-NIA and a Co-Investigator in multiple others. His research work has resulted in more than 200 original PubMed publications in highly esteemed journals (>14000 Scopus citations, Scopus h-index = 67) and multiple presentations in internationally acclaimed scientific conferences - meetings. He reviews for more than 200 international scientific journals and international funding agencies including the Alzheimer’s Association, the US National Institute of Health, the European Union programs (i.e. Marie Curie, European Research Council) etc.
For more information regarding Dr Scarmeas’ work see: https://www.ncbi.nlm.nih.gov/pubmed?cmd=search&term=Scarmeas+N%5Bau%5D&dispmax=50

Prof. Dr. Jim van Os is Professor of Psychiatry and Chairman of the Division Neuroscience at Utrecht University Medical Centre. He is also Visiting Professor of Psychiatric Epidemiology at the Institute of Psychiatry in London.
He has more than 30 years clinical experience in the treatment of severe mental illness, particularly psychotic disorders and bipolar disorder, working in a position of clinical leadership at Maastricht University Medical Centre and later at Utrecht University Medical Centre in the Netherlands, where he supervised more than 75 PhD theses.
In his area of clinical psychiatric epidemiology and public mental health, he is part of an international movement overseeing extensive pilots of recovery-based and e/mHealth-based disruptive mental health service transformation in the Netherlands and elsewhere in the world.
He works at the interface of 'hard' brain science, health services research, art and subjective experiences of people with 'lived experience' in mental healthcare. In 2014 he published his book 'Beyond DSM-5', and in 2016 the book ‘Good Mental Health Care’.
Van Os was a member of the Psychosis Workgroup of DSM5, and coordinator of the European FP7 EUGEI project, a 12 million euro grant to investigate the impact of the social environment on psychosis.
He has been a member of the Royal Netherlands Academy of Arts and Sciences (KNAW) since 2011 and was appointed Fellow of King's College London in 2016.
Van Os has been appearing on the Thomson-Reuter Web of Science list of 'most influential scientific minds of our time' since 2014. He is a member of the editorial board of many major European and American scientific journals such as Acta Psychiatrica Scandinavica, European Psychiatry, Psychological Medicine, Schizophrenia Research, Schizophrenia Bulletin, Early Intervention in Psychiatry, Epidemiology and Psychiatric Sciences, Psychosis Journal, The Journal of Mental Health and the Journal of Psychiatry and Neurological Sciences. He is also an Academic Editor at PLoSONE.

Luis A Rohde, MD, PhD is Professor of Child and Adolescent Psychiatry in the Department of Psychiatry at the Federal University of Rio Grande do Sul, Brazil, Director of the Program for Attention-Deficit/Hyperactivity Disorder at the Hospital de Clinicas de Porto Alegre, and Vice-Coordinator of the National Institute of Developmental Psychiatry for Children and Adolescent, Brazil. He is currently Associate Editor of the Journal of Attention Disorders. He served as International Editor of the J Am Acad Child and Adolescent Psychiatry (2008-2017) and as Co-Editor of the European Child and Adolescent Psychiatry (2004-2013).
He is Immediate Past President of the World Federation of ADHD and was former Vice-President of the International Association of Child and Adolescent Psychiatry and Allied Professions. He was also a member of the American Psychiatric Association working group for defining ADHD diagnosis in the DSM-5.
Dr. Rohde’s research interests include ADHD epidemiology, genetics, pharmacogenetics, neuroimaging, and the effects of pharmacological and psychosocial treatments for ADHD. He has published extensively in peer review international and national journals (400 papers) and has been an author or co-author in over 50 book chapters and editorials. He is editor or organizer of 8 books addressing child and adolescent mental health published in Brazil, UK, Germany, and the US. He has 34000 citations per doc and an H index = 78 (google scholar). In 2020, he was included as a “Highly Cited Researcher” in Psychiatry and Psychology for the last decade by Clarivate – Web of Science (top 1%).